Conference
P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC
Authors
Hellmann MD; Cho BC; Juergens R; Cheng Y; De Castro G; Erman M; Bauman JR; Takahashi T; Schwarzenberger P; Zhang P
Volume
16
Pagination
pp. s1010-s1011
Publisher
Elsevier
Publication Date
October 2021
DOI
10.1016/j.jtho.2021.08.331
Conference proceedings
Journal of Thoracic Oncology
Issue
10
ISSN
1556-0864